BR112012006253A2 - benzodiazepinas-[1,4] como antagonistas dos receptores da vasopressina v2 - Google Patents

benzodiazepinas-[1,4] como antagonistas dos receptores da vasopressina v2

Info

Publication number
BR112012006253A2
BR112012006253A2 BR112012006253A BR112012006253A BR112012006253A2 BR 112012006253 A2 BR112012006253 A2 BR 112012006253A2 BR 112012006253 A BR112012006253 A BR 112012006253A BR 112012006253 A BR112012006253 A BR 112012006253A BR 112012006253 A2 BR112012006253 A2 BR 112012006253A2
Authority
BR
Brazil
Prior art keywords
vasopressin
receptor antagonists
benzodiazepines
derivatives
compounds
Prior art date
Application number
BR112012006253A
Other languages
English (en)
Inventor
Ann Meulemans
Erik Keller
Igor Alexnadrovich Mezine
Karel Lavrijsen
Leen Thielemans
Maarten Van Geffen
Marina Cools
Original Assignee
Shire Movetis N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0916792A external-priority patent/GB0916792D0/en
Priority claimed from GBGB1013708.1A external-priority patent/GB201013708D0/en
Application filed by Shire Movetis N V filed Critical Shire Movetis N V
Publication of BR112012006253A2 publication Critical patent/BR112012006253A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

''benzodiazepinas-[1,4] como antagonistas dos receptores da vasopressina v2''. a presente invenção refere-se a uma nova classe de derivados da benzodiazepina-[1,4], a processos para a sua preparação, a intermediários utilizáveis nestes processos e a composições farmacêuticas contendo os compostos. outros aspectos da invenção são direcionados para o uso dos ditos derivados da benzodiazepiona-[1,4] em terapias baseadas na capacidade dos referidos compostos, para interferir na ligação da hormônio peptídico, a vasopressina, com os seus receptores. em particular, como antagonistas dos receptores da vasopressina v2, e, portanto, útil para tratamentos envolvendo o aumento da resistência vascular, insuficiência cardíaca e retenção de água.
BR112012006253A 2009-09-24 2010-09-23 benzodiazepinas-[1,4] como antagonistas dos receptores da vasopressina v2 BR112012006253A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0916792A GB0916792D0 (en) 2009-09-24 2009-09-24 (1,4)-Benzodiazepines as vasopressin V2 receptor antagonists
GBGB1013708.1A GB201013708D0 (en) 2010-08-16 2010-08-16 [1,4]-Benzodiazepines as vasopressin v2 receptor antagonists
PCT/EP2010/064044 WO2011036204A1 (en) 2009-09-24 2010-09-23 [1,4]-benzodiazepines as vasopressin v2 receptor antagonists

Publications (1)

Publication Number Publication Date
BR112012006253A2 true BR112012006253A2 (pt) 2016-05-31

Family

ID=43244717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006253A BR112012006253A2 (pt) 2009-09-24 2010-09-23 benzodiazepinas-[1,4] como antagonistas dos receptores da vasopressina v2

Country Status (13)

Country Link
US (1) US20120184537A1 (pt)
EP (1) EP2480538A1 (pt)
JP (1) JP2013505914A (pt)
KR (1) KR20120099415A (pt)
CN (1) CN102510859A (pt)
AU (1) AU2010299916A1 (pt)
BR (1) BR112012006253A2 (pt)
CA (1) CA2772284A1 (pt)
IL (1) IL218170A0 (pt)
MX (1) MX2012003486A (pt)
SG (1) SG179056A1 (pt)
WO (1) WO2011036204A1 (pt)
ZA (1) ZA201202150B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951874T3 (es) * 2017-09-05 2023-10-25 Neumora Therapeutics Inc Antagonistas del receptor de vasopresina y productos y métodos relacionados con los mismos
JP2021014406A (ja) * 2017-10-25 2021-02-12 トーアエイヨー株式会社 バソプレシン受容体拮抗剤
EP3875078A1 (en) * 2020-03-06 2021-09-08 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL205704B1 (pl) * 1999-01-19 2010-05-31 Ortho Mcneil Pharm Inc Związki tricyklicznej benzodiazepiny, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
EP1809296A4 (en) * 2004-10-28 2009-03-11 Janssen Pharmaceutica Nv NEW [1,4] -BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
CN102510859A (zh) 2012-06-20
JP2013505914A (ja) 2013-02-21
IL218170A0 (en) 2012-07-31
KR20120099415A (ko) 2012-09-10
WO2011036204A1 (en) 2011-03-31
MX2012003486A (es) 2012-07-17
EP2480538A1 (en) 2012-08-01
ZA201202150B (en) 2012-11-28
CA2772284A1 (en) 2011-03-31
US20120184537A1 (en) 2012-07-19
AU2010299916A1 (en) 2012-03-08
SG179056A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2012008603A (es) Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
BRPI0512630A (pt) compostos de amido e seu uso como produtos farmacêuticos
BRPI0510736A (pt) compostos de amido e seu uso como produtos farmacêuticos
BR112012011710A2 (pt) composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso
BR112012004696B8 (pt) composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação
CL2011002255A1 (es) Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras.
BR112013026828A2 (pt) polipeptídeos de anticorpo que antagonizam cd40
BRPI0514230A (pt) compostos de amido e seu uso como produtos farmacêuticos
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
BRPI0518281A2 (pt) inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
WO2009011544A3 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
GB201201314D0 (en) Composition
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]